Galectin Therapeutics Reports On Key 2013 Scientific, Development And Regulatory Milestones, Highlights Corporate And Financial Activity
Published: Jan 08, 2014
NORCROSS, Ga., Jan. 8, 2014 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today released a report on the Company's key scientific, development and regulatory milestones and corporate activity that contributed to the Company's progress in 2013.
Help employers find you! Check out all the jobs and post your resume.